UG环球国际

Be the most trusted biotech company

2026-02-16

U.S. FDA Clears IND for Phase 1 Study of Henlius’ Subcutaneous Daratumumab Biosimilar
2026-02-11

First Patient Dosed for a Phase 1b/2 Clinical Trial of PD-L1 ADC HLX43 Combination Therapy in Advanced Colorectal Cancer
2026-02-05

Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
2026-02-02

Henlius Holds U.S. Investigator Meeting for HLX22-GC-301, a Head-to-Head Phase 3 Trial vs Standard of Care (±Pembrolizumab) in HER2+ Gastric Cancer
2026-01-30

Henlius and Chongqing Pharmaceutical Group Enter into Strategic Collaboration for Shared Growth
2026-01-27

Henlius Receives an IND Approval for Its PD-L1-Targeting ADC HLX43 in Combination with Anti-PD-1 mAb Serplulimab and Novel Anti-EGFR mAb HLX07
2026-01-20

Henlius Receives NMPA Approval to Initiate Phase 1b/2 Clinical Trial of Novel SIRPα-Fc Fusion Protein HLX701 for Advanced RAS/BRAF Wild-type Colorectal Cancer
2026-01-16

Henlius Showcases “Globalisation 2.0” Strategy and Mid-to-Long-Term Innovation Blueprint at JPM 2026
2026-01-14

Henlius Strengthens Autoimmune-Inflammation Portfolio by In-Licensing a Novel, Best-in-Class Potential Anti-IL-1RAP mAb

1
...
6
7
8
9
10